基于生物信息学分析LY6D在胰腺癌中的表达、发病机制及预后评估价值

Analysis of the Expression, Pathogenesis and Prognostic Value of LY6D in Pancreatic Adenocarcinoma, Based on Bioinformatics

摘要: 目的：探究LY6D在胰腺癌中的表达、预后意义，以及致病机制，并构建预后评估模型。方法：Timer2.0在线网站分析LY6D在各种肿瘤中的表达，GEO数据集分析LY6D在胰腺癌中的表达。cbioportal分析LY6D突变对胰腺癌患者预后的影响，Kaplan-Meier Plotter在线网站分析LY6D表达对胰腺癌患者预后的影响，GSEA富集分析探索LY6D在胰腺癌中参与的信号通路，STRING数据库构建PPI网络探究与LY6D关系密切的基因，最后利用与胰腺癌预后显著相关的基因构建预后模型。结果：LY6D在胰腺癌中显著高表达，且LY6D高表达患者具有较差预后，同时LY6D突变胰腺癌患者具有较差预后，LY6D富集到细胞粘附通路中，通过促进癌细胞粘附和扩散促进癌症的进展，基于LY6D、PSCA、MSLN构建的预后模型对胰腺癌患者预后评估具有显著意义。结论：LY6D有望成为胰腺癌早期诊断的重要标志物和作为分子治疗的重要靶点。基于LY6D、MSLN、PSCA构建的预后模型对胰腺癌患者预后具有较好的评估价值。

Abstract: Object: To investigate the expression, prognostic significance and pathogenesis of LY6D in pancreatic adenocarcinoma, and to establish a prognostic evaluation model. Methods: Timer2 database was used to analyze the expression of LY6D in various tumors and GEO data sets were used to analyze the expression of LY6D in pancreatic adenocarcinoma. Cbioportal website was used to analyze the effect of LY6D mutation on the prognosis of patients with pancreatic adenocarcinoma. The Kaplan-Meier Plotter online website analyzed the effect of LY6D expression on the prognosis of pancreatic adenocarcinoma patients. GSEA enrichment analysis explored the signal pathway of LY6D in pancreatic adenocarcinoma. The PPI network was constructed with string database to explore the genes closely related to LY6D. Finally, a prognostic model was constructed based on the genes associated with the prognosis of pancreatic adenocarcinoma. Results: LY6D was highly expressed in pancreatic adenocarcinoma, and patients with high LY6D expression had poor prognosis. Meanwhile, patients with pancreatic adenocarcinoma with LY6D mutation have poor prognosis. LY6D is enriched into the cell adhesion pathway and promotes the progression of cancer by promoting the adhesion and proliferation of cancer cells. The prognosis model based on LY6D, PSCA and MSLN has significant significance in the prognosis evaluation of pancreatic adenocarcinoma patients. Conclusion: LY6D is expected to be an important marker for early diagnosis of pancreatic adenocarcinoma and an important target for molecular therapy. The prognosis model based on LY6D, MSLN and PSCA has significant value in predicting the prognosis of patients with pancreatic adenocarcinoma.